Dalrada Financl Stock Price, News & Analysis

Dalrada Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as President of its subsidiary, Dalrada Health. With over 35 years in the healthcare sector, his experience is expected to bolster the company’s growth and expansion initiatives. Dalrada Health is involved in multiple segments, including GlanHealth™ and Pala Diagnostics, and has achieved significant milestones in healthcare services, including the launch of COVID-19 on-site testing. The global healthcare services market is projected to grow at a CAGR of 7% to $9,725.4 billion by 2023, positioning Dalrada favorably in this evolving landscape.

Dalrada Corporation (DFCO) has reported impressive financial results for Q1 ending September 30, 2021, with revenues of $4,602,353, a remarkable 506% increase from $759,393 in Q1 2020. Gross profit surged to $3,398,018, up 546% from $525,965 the previous year. The stockholder deficit decreased by 48%. Dalrada's strong performance comes alongside growth in its healthcare and technology divisions, despite increased operating expenses due to various expansions and compensations.

Dalrada Corporation (OTCQB: DFCO) announces the opening of two new healthcare facilities in California, including the Sòlas Rejuvenation + Wellness clinic and Empower Genomics laboratory. These facilities aim to enhance public access to personalized health solutions and virology testing, including on-site COVID-19 testing. Sòlas offers a range of advanced medical and therapy services in a 56,510-square foot center in Poway, California. The company emphasizes its commitment to addressing global health challenges through innovative solutions and partnerships.

Dalrada Corporation (OTCQB: DFCO) announced the authorization of 10,002 Convertible Series “G” Preferred Shares at a par value of $0.01 each on September 23. This move will convert $6,532,188 from liabilities to Owner’s Equity. The investors agreed to waive penalties and default interest after September 30, 2021. This transaction indicates a positive shift in equity management. Dalrada has made significant advances in technology, engineering, and health sectors, enhancing revenues and operating profits during fiscal year 2021. The company aims to provide innovative solutions across its three divisions.

Dalrada Corporation (DFCO) has signed a letter of intent to acquire Advanced DME Services, also known as Advanced Homecare, a Southern California-based provider focusing on sleep apnea solutions. This strategic acquisition aims to establish a new subsidiary within Dalrada Health, expanding its market reach and enhancing growth opportunities. Advanced Homecare has served nearly 40,000 patients since 2005, and its revenue reached $10 million in 2020. The acquisition aligns with Dalrada's mission to improve healthcare solutions and is backed by coverage from major insurance providers.

Dalrada Corporation (DFCO) has been recognized as one of the Best San Diego-Based Clean Energy Companies. The company aims to innovate solutions for complex problems in clean energy, industrial engineering, health, and wellness. Dalrada's subsidiary, Likido®, received accolades for its innovation and societal impact. Likido® energy solutions focus on reducing greenhouse gas emissions and improving energy efficiency, with products like Likido®ONE and Likido®CRYO. The company emphasizes corporate social responsibility and environmental stewardship.

Dalrada Corporation (DFCO) has established a Clean Energy Advisory Board, featuring significant leaders in climate and business, including former U.S. Secretary of the Interior, Ryan Zinke. The board aims to forge strategic alliances for sustainable development and responsible environmental policies. Zinke emphasizes the importance of energy-efficient technologies that reduce carbon footprints. Dalrada's innovative low-carbon heating and cooling technology utilizes supercritical CO2, aiming to enhance energy efficiency while minimizing emissions.

Dalrada Corporation (OTCQB: DFCO) announced a remarkable 189% revenue surge to $3,406,684 for fiscal year 2021, compared to $1,178,154 in 2020. The growth was fueled by its subsidiaries: Dalrada Health, Dalrada Technology, and Dalrada Precision. Highlights included key acquisitions, product launches, and client expansions. Operating expenses rose to $9,504,869 from $3,241,335 due to increased activity. Despite this, Dalrada reported a net income of $1,221, rebounding from a net loss of $2,477,557 the previous year. The company’s board continues to attract industry leaders to drive innovation.

Dalrada Corporation (OTCQB: DFCO) has announced its community outreach initiative providing free COVID-19 point-of-care tests at events, including the Boise Pride Festival. Pala Diagnostics, a joint venture with Vivera Pharmaceuticals, administered nearly 3,000 rapid antigen and PCR tests, ensuring compliance with health protocols. The collaboration aims to restore safe public gatherings, reflecting the company's commitment to innovative health solutions. As part of its strategy, Dalrada focuses on disruptive solutions across its business divisions to address global challenges.